Evidence map›Paper›PMID 42662206›Full record

ArticleACS omega2026

Design, Synthesis, and Antileishmanial Activity of Novel C6-Substituted Eugenol Derivatives with a Triazole Linker.

Henrique P Orenha, Fabiana M S U Moncorvo, Thiago Dos Santos, Guilherme Espírito Santo da Silva, Victor H C Fernandes, Eduardo Caio Torres-Santos, Giuliano C Clososki

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Henrique P OrenhaDepartment of BioMolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Avenida do Café s/n, Vila Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0003-0662-3519
Fabiana M S U MoncorvoLaboratory of Trypanosomatid Biochemistry, Oswaldo Cruz Institute - Fiocruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ 21040-360, Brazil.
Thiago Dos SantosDepartment of BioMolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Avenida do Café s/n, Vila Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0001-7908-8604
Guilherme Espírito Santo da SilvaLaboratory of Trypanosomatid Biochemistry, Oswaldo Cruz Institute - Fiocruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ 21040-360, Brazil.
Victor H C FernandesDepartment of BioMolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Avenida do Café s/n, Vila Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil.
Eduardo Caio Torres-SantosLaboratory of Trypanosomatid Biochemistry, Oswaldo Cruz Institute - Fiocruz, Avenida Brasil 4365, Manguinhos, Rio de Janeiro, RJ 21040-360, Brazil.ORCID https://orcid.org/0000-0003-2240-4519
Giuliano C ClososkiDepartment of BioMolecular Sciences, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Avenida do Café s/n, Vila Monte Alegre, Ribeirão Preto, SP 14040-903, Brazil.ORCID https://orcid.org/0000-0001-7605-4150

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among tropical neglected diseases, leishmaniasis stands out. This parasitic infection occurs in numerous countries, affecting thousands of people worldwide. The currently available therapies present important limitations, including high toxicity, long treatment periods requiring parenteral administration, and the emergence of parasite resistance. Based on the known antileishmanial properties of eugenol and its derivatives, a series of novel disubstituted 1,2,3-triazoles was prepared via the classical 1,3-dipolar cycloaddition reaction, employing a eugenol-azide derivative. These compounds were subsequently evaluated against

Identifiers

PMID42662206
PMCPMC13520032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.